4.7 Review

C-reactive protein and coronary heart disease: a critical review

Journal

JOURNAL OF INTERNAL MEDICINE
Volume 264, Issue 4, Pages 295-314

Publisher

WILEY
DOI: 10.1111/j.1365-2796.2008.02015.x

Keywords

coronary heart disease; C-reactive protein

Funding

  1. Medical Research Council [7900510]
  2. National Heart Lung and Blood Institute of the US NIH [1 R01 HL078578-01]
  3. Pentraxin Therapeutics Ltd
  4. British Heart Foundation [FS/05/125]
  5. Rosetrees Trust
  6. Wellcome Trust
  7. BUPA Foundation
  8. GlaxoSmithKline
  9. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078578] Funding Source: NIH RePORTER
  10. British Heart Foundation [RG/08/014/24067] Funding Source: researchfish
  11. Medical Research Council [G7900510] Funding Source: researchfish
  12. MRC [G7900510] Funding Source: UKRI

Ask authors/readers for more resources

Modestly elevated baseline concentrations of C-reactive protein (CRP), the classical acute phase protein, are associated with the long-term risk of coronary heart disease in general populations, whilst the major acute phase response of CRP following myocardial infarction is associated with death and cardiac complications. The pathogenic and clinical significance of these associations is controversial. Here we critically review the evidence and describe large-scale epidemiological studies, novel experiments and possible specific therapies which will rigorously inform the debate. We distinguish between the potential pathogenicity of high acute phase circulating CRP concentrations in individuals with substantial tissue damage and modest but persistent increases in baseline values in generally healthy subjects.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available